Every Form 4 that The Oncology Institute Inc (TOI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TOI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TOI filings page.
Starling Oncology, Inc. insider Jorey Chernett, a more-than-10% owner, reported mixed transactions in company securities. On 2026-08-14, Chernett purchased 12,000 shares of common stock at $6.54 per share, bringing direct holdings to 10,660,858 shares. On 2026-08-13, Chernett sold 100 call option contracts on Starling Oncology (each linked to 100 shares, or 10,000 underlying common shares) with a $9.00 exercise price and 19-Feb-2027 expiration, at $6.24 per option. According to a footnote, this option sale is treated as a matchable transaction under Section 16(b), and Chernett intends to disgorge the calculated short-swing profit to the issuer.
Kaushal Mohit reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director Kaushal Mohit received a grant of 33,133 restricted stock units (RSUs) of common stock on July 27, 2026. Each RSU entitles him to one share of common stock upon settlement.
The RSUs vest in full at the company’s 2027 annual meeting of stockholders, subject to his continued service with the company on the vesting date. Following this award, his reported direct holdings total 205,716 shares of common stock.
McGeorge Anne reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that director Anne McGeorge received a grant of 41,165 restricted stock units (RSUs) of common stock. Each RSU entitles her to one share upon settlement and vests in full on the date of the company’s 2027 annual meeting of stockholders, subject to her continued service. Following this award, her direct holdings total 332,535 shares of common stock.
Pacala Mark L reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director Mark L. Pacala received an equity award of 30,120 restricted stock units (RSUs), each settling into one share of common stock. The RSUs vest in full at the company’s 2027 annual meeting of stockholders, subject to his continued service, bringing his direct holdings to 286,881 shares.
STOLPER MARK reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director Mark Stolper reported an equity compensation grant of 31,124 shares of Common Stock in the form of restricted stock units (RSUs) on 2026-07-27. Each RSU entitles him to receive one share of common stock upon settlement and vests in full on the date of the company’s 2027 annual meeting of stockholders, contingent on his continued service through that date. Following this award, Stolper directly holds 56,957 shares of common stock. The RSUs were granted at a stated price of $0.00 per share, reflecting their nature as a compensation grant rather than a market purchase.
TZOUMAKAS KIMBERLY JO reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director TZOUMAKAS KIMBERLY JO received a grant of 29,116 restricted stock units on July 27, 2026, each entitling her to one share of common stock upon settlement. These RSUs vest in full at the 2027 annual meeting of stockholders, bringing her direct holdings to 46,301 shares.
Hively Brad reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that director Brad Hively received an equity grant of 27,108 shares of common stock on July 27, 2026, structured as restricted stock units (RSUs) at a stated price of $0.0000 per share. Each RSU entitles him to one share of common stock upon settlement and vests in full on the date of the company’s 2027 annual meeting of stockholders, subject to his continued service with the company through that date. Following this award, Hively directly holds 710,829 shares of Oncology Institute common stock.
Johnson Karen Marie reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. granted director Karen Marie Johnson 31,124 restricted stock units (RSUs), each convertible into one share of common stock. The RSUs vest in full at the company’s 2027 annual meeting of stockholders, subject to her continued service, increasing her direct holdings to 319,410 shares.
Oncology Institute, Inc. ten percent owner Jorey Chernett purchased 18,000 shares of Common Stock on July 21, 2026 at a weighted average price of $5.27 per share in open-market or private transactions. Following this transaction, Chernett directly owns 10,648,858 shares of Oncology Institute common stock. The reported price reflects multiple trades between $5.27 and $5.28 per share, based on the weighted-average pricing disclosure.
Oncology Institute, Inc. Chief Medical Officer Yale Podnos reported an option exercise-and-sale sequence on July 14, 2026. He exercised stock options for a total of 23,452 common shares at strike prices of $2.00 and $1.87, then sold all corresponding shares in open-market trades at prices of $6.35 and $6.429. The transactions were executed under a pre-arranged Rule 10(b) 5-1 trading plan. Following these trades, he directly holds 259,527 shares of common stock.
Oncology Institute, Inc. major shareholder Jorey Chernett, a more than ten percent owner, reported an open-market purchase of 15,000 shares of common stock on July 10, 2026, at a weighted average price of $5.85 per share. The purchase was executed in multiple transactions at prices ranging from $5.82 to $5.90 per share, based on the footnote disclosure. Following this transaction, Chernett directly holds 10,630,858 shares of Oncology Institute common stock.
TZOUMAKAS KIMBERLY JO reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director Kimberly Jo Tzoumakas received a fully vested restricted stock unit (RSU) award of 17,185 shares of common stock on July 7, 2026. The grant is recorded at a price of $0.00 per share as equity compensation rather than an open-market purchase, and her directly held stake after this award is 17,185 shares.
STOLPER MARK reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director Mark Stolper reported an equity compensation grant of 25,833 shares of Common Stock on July 7, 2026. The Form 4 classifies this as a grant or award (code A) at a stated price of $0.00 per share, reflecting a non-cash award. A footnote explains that the grant represents an RSU award that was fully vested upon grant. Following this transaction, Stolper directly owns 25,833 shares of Oncology Institute common stock.
Oncology Institute, Inc. ten percent owner Jorey Chernett bought 18,000 shares of Common Stock in an open-market purchase. The shares were acquired on June 23, 2026 at a weighted average price of $5.02 per share, in trades ranging from $5.02 to $5.04. After this transaction, Chernett directly owns 10,615,858 shares of Oncology Institute common stock.
Oncology Institute, Inc. Chief Medical Officer Yale Podnos reported an open-market sale of 23,451 shares of common stock on June 8, 2026 at a volume-weighted average price of $5.3769 per share. After this transaction, he continues to hold 259,527 shares directly. The filing notes the sale prices ranged from $5.35 to $5.42 and that the trades were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on August 26, 2025.
Chernett Jorey, a ten percent owner of Oncology Institute, Inc., reported an open-market purchase of 12,000 shares of Common Stock on June 4, 2026 at $4.75 per share. Following this transaction, Jorey directly holds 10,579,858 shares of Oncology Institute common stock.
Oncology Institute, Inc. Chief Medical Officer Yale Podnos reported an administrative share transaction involving 1,805 shares of common stock at $4.47 per share. According to a footnote, the issuer executed this sale to cover tax liabilities from the vesting of a restricted stock unit award granted on May 21, 2024. Following this transaction, Podnos directly holds 282,978 shares of common stock, indicating that the event represents a small, routine adjustment related to equity compensation rather than a discretionary market trade.
Oncology Institute, Inc. Chief Executive Officer Daniel Virnich reported an administrative equity transaction involving 23,058 shares of common stock. According to the footnote, the issuer executed a sale of these shares to cover tax liabilities arising from the vesting of a restricted stock unit (RSU) award made on May 21, 2024.
Following this tax-related transaction, Virnich directly holds 2,337,166 shares of common stock. The filing does not show any open-market buying or selling by him, but rather a routine step connected to equity compensation and associated taxes.
Oncology Institute, Inc.’s Chief Financial Officer Robert Ross reported a small administrative share transaction. The issuer sold 1,604 shares of common stock at $4.47 per share to cover tax liabilities from the vesting of an RSU award granted on May 21, 2024. After this tax-related sale, Ross directly holds 414,801 shares of common stock, indicating his overall ownership position remains largely unchanged.
Oncology Institute, Inc. major shareholder Jorey Chernett reported open‑market purchases of the company’s Common Stock. He bought 5,000 shares on May 19, 2026 at $4.05 per share and 33,500 shares on May 20, 2026 at a weighted average price of $4.07 per share.
Following these transactions, Chernett directly owns 10,567,858 shares of Oncology Institute Common Stock, reflecting additional accumulation by a ten percent owner.
Oncology Institute, Inc. insider Jorey Chernett, identified as a ten percent owner, reported an open-market purchase of common stock. Chernett bought 30,000 shares on May 19, 2026 at a price of $4.09 per share. After this transaction, Chernett directly owns 10,529,358 common shares, indicating the purchase modestly increased an already large existing position.
Oncology Institute, Inc. filed a Form 4 for Chief Administrative Officer Kristin England that shows no reportable insider trades during the period covered. The filing lists zero purchases, zero sales, zero derivative exercises, and no gifts, tax withholdings, or restructuring-related transfers.
Oncology Institute, Inc. insider Jeffrey Langsam, the company’s Chief Clinical Officer, filed a Form 4 reporting his status as an officer but no transactions in company securities. The provided data show no purchases, sales, exercises, gifts, or other changes in his reported holdings.
Oncology Institute, Inc. director Mohit Kaushal reported open-market sales of 95,719 shares of Common Stock. He sold 57,286 shares on April 14, 2026 at a volume-weighted average price of $3.5017 per share and 38,433 shares on April 16, 2026 at a volume-weighted average price of $3.5005 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025. Following the reported sales, Kaushal directly holds 172,583 shares of Oncology Institute common stock.
Oncology Institute, Inc. ten percent owner Jorey Chernett reported an open-market purchase of common stock. On April 9, 2026, Chernett bought 20,000 shares at $3.10 per share. After this purchase, Chernett directly owned 10,499,358 common shares.
Langsam Jeffrey reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that its Chief Clinical Officer, Jeffrey Langsam, received a grant of 70,270 shares of common stock in the form of restricted stock units. These RSUs were granted at no cash cost per share and increase his direct holdings to 127,650 shares after the award.
The footnote explains that one quarter of the RSUs will vest on the first anniversary of the Vesting Commencement Date, with the remaining units vesting in three equal annual installments on each of the next three anniversaries. All RSUs are subject to continued service with the company through the respective vesting dates.
England Kristin reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that Chief Administrative Officer Kristin England received a grant of 55,743 shares of common stock in the form of restricted stock units (RSUs) at no cash cost. Following this award, she directly holds 153,780 shares of the company’s common stock.
The RSUs vest over four years, with one quarter vesting on the first anniversary of the vesting commencement date and the remaining three quarters vesting in equal annual installments on each of the next three anniversaries, subject to her continued service with the company.
Podnos Yale reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that its Chief Medical Officer, Yale Podnos, received a grant of 66,446 shares of common stock on March 27, 2026 at no cost as part of a restricted stock unit (RSU) award. According to the terms, one quarter of the RSUs vest on the first anniversary of the vesting commencement date, with the remaining portions vesting in three equal annual installments so that all units vest by the fourth anniversary, subject to continued service. The issuer also executed a sale of 16,173 shares at $3.07 per share to cover tax liabilities arising from the vesting of an RSU award on March 31, 2026, a mechanistic tax-related transaction rather than an open-market trade.
Carter Robert Ross reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that Chief Financial Officer Robert Ross received a grant of 202,914 shares of common stock in the form of restricted stock unit (RSU) awards. The RSUs vest over four years, with one quarter vesting on the first anniversary of the vesting start date and the remainder in three equal annual installments, subject to continued service. The company also executed a sale of 20,320 shares at $3.07 per share to cover tax liabilities arising from an RSU vesting on March 31, 2026. Following these transactions, Ross directly holds 416,405 common shares.
Virnich Daniel reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. CEO Daniel Virnich reported equity compensation activity. He received a grant of 670,608 shares of common stock as RSU awards at $0.00 per share, which vest over four years subject to continued service. Separately, the issuer executed a sale of 98,534 shares at $3.07 per share to cover tax liabilities arising from RSU vesting on March 31, 2026. After these transactions, Virnich directly holds 2,360,224 common shares.
Oncology Institute, Inc. ten percent owner Jorey Chernett reported an open-market purchase of 27,429 shares of Common Stock at a price of $2.96 per share. Following this transaction, he directly owns 10,479,358 common shares, indicating a modest increase to an already large position.
Oncology Institute, Inc. ten percent owner Jorey Chernett bought 25,000 shares of Common Stock in an open‑market transaction. The weighted average purchase price was about $3.35 per share, with individual trades between $3.33 and $3.35.
After this purchase, Chernett directly owns 10,276,929 Oncology Institute shares.
Oncology Institute, Inc. disclosed that 10% owner Jorey Chernett made three open-market purchases of Common Stock, totaling 398,985 shares, at reported weighted average prices of about $2.92–$3.42 per share. Following these transactions, he directly owns 10,251,929 shares. The footnotes explain that each reported price is a weighted average for multiple trades within specified intraday price ranges.
The Oncology Institute, Inc. chief financial officer reports a small stock sale linked to taxes. On January 2, 2026, the reporting officer sold 247 shares of Oncology Institute common stock at a price of $3.56 per share. After this transaction, the officer beneficially owned 235,122 shares directly.
The filing notes that the proceeds from this sale were used to cover tax liabilities arising from the vesting of a restricted stock unit (RSU) award on January 1, 2026. This indicates the transaction was tied to compensation-related tax obligations rather than a discretionary reduction in holdings.
Oncology Institute, Inc. director Gabriel Ling filed a Form 4 as a single reporting person in connection with Oncology Institute, Inc. common stock. The filing lists Ling’s role as a director of the company and shows an earliest transaction date of 12/01/2025, but the transaction tables in the excerpt do not display any specific share amounts, prices, or derivative positions.
Oncology Institute (TOI) Chief Executive Officer Daniel Virnich reported an insider equity award. The Form 4 shows 6,211 shares of common stock acquired at $0.00 on 11/12/2025, reflecting RSUs that were fully vested upon grant and settled net of withholding taxes. Following this transaction, he beneficially owned 1,793,520 shares, held directly.
Oncology Institute, Inc. (TOI) insider activity: A Form 4 reports that the company’s Chief Medical Officer acquired common stock via restricted stock units (RSUs) that were fully vested upon grant on 11/12/2025.
The filing lists two RSU-related acquisitions at a price of $0.00 per share: 306 shares and 1,202 shares, reported as net of withholding tax obligations. Following these transactions, the reporting person beneficially owned 235,844 shares.